OBX-115: A new TIL engineered with IL15 and DRD.

Inside Apoha’s Liquid Brain: A New Way to Tackle Antibody Developability https://lnkd.in/efyGwYpb As drug development pushes into more complex antibody formats, how do you really assess developability? In this episode of The Chain, host Nimish Gera and Apoha CEO Shamit Shrivastava dive into Liquid Brain, Apoha’s interdisciplinary approach that’s changing the way researchers tackle developability of challenging antibody-based drugs and give a preview of what to expect at PEGS Europe this November. Listen: https://lnkd.in/efyGwYpb

https://lnkd.in/dSGbU2kz We are pleased to introduce the ADLib® System, Chiome’s proprietary monoclonal antibody generation technology based on a cell surface display method, in a four-minute video.

Unlock atomic-level insights with FairJourney Biologics’ cryoEM-based Epitope Mapping Service. In under 1 week, after receiving the VHH's and target protein, we: - Reconstructed a 2.9 Å density map - Built a validated structural model - Delivered key insights into the VHH’s binding mode These results not only explained specificity but also enabled structure-based candidate selection. With this atomic-level detail of the epitope-paratope interface, we generated the framework needed for in silico affinity maturation through our Structure-Based Design Service. Rapid, precise, and actionable data – turning discovery into design. 👉 Learn more about how FJB can accelerate your antibody development journey: www.fjbio.com #AntibodyDiscovery #cryoEM #EpitopeMapping #StructureBasedDesign #AntibodyEngineering

🫁 Case Study: Quantitative imaging in the Fibroblast-to-Myofibroblast Transition (FMT) assay The challenge❓ To evaluate three anti-fibrotic drug candidates in an FMT assay. We used high content imaging (HCI) to assess their effects on two disease-relevant markers This high-throughput study generated over 1,000 data points and was completed in just over a month. Read the full case study here 👉 https://lnkd.in/eHJ5WSFT #Newcells #Fibroblasts #LungModels #HighContentImaging #Pharma

Potency, efficacy, intrinsic activity — what do they actually tell you about an agonist? Here’s a quick guide you can use at a glance. At Gifford Bioscience, our functional assays (GTPγS, cyclic AMP and calcium) quantify how strongly and how effectively ligands activate receptors, allowing you to distinguish full agonists, partial agonists, inverse agonists, and everything in between. Here are some important metrics functional assays can provide: Emax describes efficacy, the maximum response produced by your drug; pEC₅₀ describes potency, the range of concentrations over which your drug produces a response; Intrinsic activity (α), how your drug compares to a full agonist in this system. When combined, these parameters reveal the balance between receptor occupancy and signalling efficiency. Essential for understanding ligand bias, receptor reserve, and translational relevance. We help you interpret these values, so your pharmacology makes biological sense, not just numerical sense. 📧info@giffbio.com 💻 www.giffordbioscience.com #DrugDiscovery #Pharmacology #BindingAssays #Radioligand #Biotech #GPCR #OncologyResearch #NeuroscienceResearch #BiotechNews #CROServices

MALDI mass spectrometry is reshaping biologics characterization — from antibody-drug conjugates and fusion proteins to oligosaccharides and lipid nanoparticles. Our timsTOF fleX, neofleX™, and rapifleX® platforms deliver speed, robustness, and flexibility across diverse workflows. Here are some of the recent highlights: 🔷 Impurity identification in biotherapeutics Merck & Co. published a universal LC-MALDI-MS workflow for rapid impurity identification across challenging LC techniques applicable to mAbs, bispecifics, ADCs, and peptides. 🔷 ADC characterization neofleX allows rapid, subunit-level detection of drug-load species and precise DAR calculation. 🔷 Human milk oligosaccharide profiling with MALDI-TIMS Quickly identify oligosaccharide isomers and classify human milk samples into types I–IV. 🔷 LNP component analysis Characterize all four key lipid nanoparticle components — including PEGylated lipids — efficiently. 👉 Explore the full MALDI Content Collection: https://lnkd.in/e7mnmmCV #Bruker #massspectrometry #MassSpec #BiologicsCharacterization #Merck #ADC #LNP #oligosacharides #biopharma #MALDI

Biogen is paying $70M upfront to Vanqua Bio for a preclinical oral C5aR1 drug — revisiting the same target it dropped after last year’s HI-Bio buyout. https://lnkd.in/ezCzbe_v

While many boast about how they leverage target genetics to increase preclinical success rates from 2 to 8%, we provide a target connectivity powered neuromap that has a 69% to 97% Phase III Clinical Failure Elimination rate to our academic, biotech and pharma partners. Discover how our biological intelligence approach can de-risk and accelerate your drug discovery, repurposing, or foundation model evaluation efforts by reviewing the 11-slide presentation provided here or contacting us.

We are excited to share our new research article, 𝗜𝗻𝘃𝗲𝘀𝘁𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁𝘀 𝗼𝗳 𝗖𝗵𝗼𝗹𝗲𝘀𝘁𝗲𝗿𝗼𝗹 𝗮𝗻𝗱 𝗟𝗶𝗽𝗶𝗱 𝗣𝘂𝗿𝗶𝘁𝘆 𝗼𝗻 𝗣𝗵𝗼𝘀𝗽𝗵𝗼𝗹𝗶𝗽𝗶𝗱 𝗦𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗶𝗻 𝗟𝗶𝗽𝗼𝘀𝗼𝗺𝗮𝗹 𝗡𝗮𝗻𝗼𝗰𝗮𝗿𝗿𝗶𝗲𝗿𝘀 𝗨𝘀𝗶𝗻𝗴 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗗𝘆𝗻𝗮𝗺𝗶𝗰𝘀 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀, in which we investigate how cholesterol content and lipid purity influence the stability of phospholipids in liposomal nanocarriers. Using molecular dynamics simulations and umbrella sampling in GROMACS, our study provides atomistic insights into lipid interactions, revealing that cholesterol significantly reduces lipid binding energy. These findings offer critical guidance for the rational design of more stable and efficient liposomal drug delivery systems, highlighting the power of computational simulations in modern pharmaceutical research. 🔗 Access the full article: https://lnkd.in/eH7h2mCa #LiposomalNanocarriers #MolecularDynamics #DrugDelivery #PhospholipidStability #Nanomedicine #BiomedicalResearch #RationalDesign

Discover the technologies shaping the future of large-scale oligonucleotide manufacturing.   Oligonucleotides are enabling new therapies; however, scaling their production can present significant challenges. Traditional synthesis methods may struggle to meet growing global demand.   Our latest whitepaper explores how enzymatic ligation and other innovative technologies are overcoming these barriers, offering higher yields, cost efficiency, sustainability, and scalability for next-generation oligonucleotide therapeutics. Inside the whitepaper: The limitations of traditional synthesis methods and the benefits of fragment synthesis and enzymatic ligation How enzymatic ligation improves cost efficiency, reduces chemical waste, and supports greener production processes The role of Bachem’s GMP-ready, multi-kilogram scale expertise in advancing drug development Download the full whitepaper today: https://bit.ly/46spHBW Interested to learn more? Register for our upcoming webinar "Efficient Large-scale siRNA Manufacturing: Enzymatic Ligation of Short RNA Fragments": https://bit.ly/46illgx #Bachem #Oligonucleotides #EnzymaticLigation #Innovation #Sustainability